OBJECTIVES: Endometrial Cancer Health Outcomes Study (ECHOS) is a multicountry real-world data study evaluating the treatment practices and health outcomes in patients with endometrial cancer (EC) in Argentina, Brazil, and Colombia. This analysis describes clinical characteristics and treatment patterns in patients from Argentina (ECHOS-A), focusing on first line (1L) antineoplastic therapy use.

METHODS: A retrospective cohort study using electronic medical records from patients with EC affiliated to a private health insurance plan (Hospital Italiano de Buenos Aires) receiving antineoplastic therapy between 01/2010 and 12/2019. Index (proxy for diagnosis) was the first date of an EC-related health term or procedure/treatment. Patients were classified as treated when exposed to surgery, radiotherapy, or antineoplastic therapy (hormone therapy [HT], chemotherapy [CT], or immunotherapy [IT]). Proportions of patients receiving systemic therapies in the 1L (dispensed within the initial 30-day cycle) and in each year of follow-up were calculated. International Federation of Gynecology and Obstetrics (FIGO) staging was evaluated among patients receiving treatment.

RESULTS: In the observation period, 805 patients received an EC diagnosis and 623 (77.4%) were treated. Among the 544 treated patients with a FIGO staging classification, 101 (18.6%) were considered advanced (III and IV), of whom only 63 (62.4%) received systemic therapy. 198 patients (31.8%) received 1L systemic therapy (CT, 82.8%; HT, 17.7%; IT, 1.0%), 81.3% within the first year. Platinum-based CT was the most frequent 1L scheme, received by 146 patients (73.7%), of which, 106 patients received the carboplatin-paclitaxel combination.

CONCLUSIONS: Among patients with EC treated with antineoplastic drugs, the majority received carboplatin and paclitaxel. However, around one-fifth received no treatment and over one-third of advanced cases were not treated with antineoplastic drugs. Efforts to better understand and address the reasons behind this are needed to help improve outcomes in the future.